NAUT
NASDAQ · Life Sciences Tools & Services
Nautilus Biotechnology Inc
$2.03
+0.01 (+0.50%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 80.17M | 80.92M | 67.58M |
| Net Income | 11.70M | 10.54M | 10.24M |
| EPS | — | — | — |
| Profit Margin | 14.6% | 13.0% | 15.2% |
| Rev Growth | +16.9% | +0.2% | +13.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 22.23M | 24.81M | 20.67M |
| Total Equity | 203.50M | 205.46M | 185.25M |
| D/E Ratio | 0.11 | 0.12 | 0.11 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 18.12M | 18.88M | 15.83M |
| Free Cash Flow | 8.11M | 11.53M | 7.63M |